© 2013

Complement Therapeutics

  • John D. Lambris
  • V. Michael Holers
  • Daniel Ricklin
  • Proceedings from the 5th International Complement Theraputics Conference

  • Part of the Aegean Conferences series

  • Incorporates cutting-edge research and showcases methods developed and perfected in the last decade


Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 735)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Daniel Ricklin, John D. Lambris
    Pages 1-22
  3. Péter Gál, József Dobó, László Beinrohr, Gábor Pál, Péter Závodszky
    Pages 23-40
  4. Hideharu Sekine, Minoru Takahashi, Daisuke Iwaki, Teizo Fujita
    Pages 41-53
  5. Berhane Ghebrehiwet, Jolyon Jesty, Rama Vinayagasundaram, Uma Vinayagasundaram, Yan Ji, Alisa Valentino et al.
    Pages 97-110
  6. Hiroshi Nishiura
    Pages 111-121
  7. Constantinos Deltas, Daniel Gale, Terence Cook, Konstantinos Voskarides, Yiannis Athanasiou, Alkis Pierides
    Pages 189-196
  8. George Hajishengallis, John D. Lambris
    Pages 197-206
  9. Mariusz Z. Ratajczak, ChiHwa Kim, Janina Ratajczak, Anna Janowska-Wieczorek
    Pages 219-232
  10. Mohammad A. Khan, Mark R. Nicolls
    Pages 233-246
  11. Steven Sacks, Julia Karegli, Conrad A. Farrar, Elham Asgari, Wilhelm Schwaeble, Wuding Zhou et al.
    Pages 247-255
  12. Kristina N. Ekdahl, Jaan Hong, Osama A. Hamad, Rolf Larsson, Bo Nilsson
    Pages 257-270
  13. Joshua M. Thurman, Bärbel Rohrer
    Pages 271-282

About this book


This book highlights progress and trends in the rapidly evolving field of complement-related drug discovery and spotlights examples of clinical applications. As an integral part of innate immunity and critical mediator in homeostatic and inflammatory processes, the human complement system has been identified as contributor to a large number of disorders including ocular, cardiovascular, metabolic, autoimmune, and inflammatory diseases as well as in ischemia/reperfusion injury, cancer and sepsis. In addition, complement is often involved in adverse immune reactions to biomaterials, cell and organ transplants or drug delivery systems. Although the complement cascade with its close to 50 extracellular protein targets has long been recognized as an attractive system for therapeutic modulation, the past few years have seen a particularly strong boost in interest. Fueled by novel research insight and the marketing of the first complement-targeted drugs, a plethora of highly creative treatment approaches and potent drug candidates have recently emerged and are currently evaluated in disease models and clinical trials.


The chapters in this book cover a wide range of topics related to the development of complement therapeutics, ranging from the molecular and functional description of complement targets to the presentation of novel inhibitors, improved treatment strategies as well as examples of disease models and clinical applications. The broad and up-to-date overview on a highly versatile and dynamic field renders this book an indispensable source of information for researchers and clinicians dealing with therapeutic and disease-related aspects of the human complement system.

Editors and affiliations

  • John D. Lambris
    • 1
  • V. Michael Holers
    • 2
  • Daniel Ricklin
    • 3
  1. 1.MedicineUniversity Of Pennsylvania Department Of Pathology Laboratory OfPhiladelphiaUSA
  2. 2.University of Colorado School of MedicinAuroraUSA
  3. 3.Department of Pathology & Laboratory MedUniversity of Pennsylvania School of MedPhiladelphiaUSA

About the editors

Progress and Trends in Complement Therapeutics.- Inhibition of the serine proteases of the complement system.- The role of MASP-1/3 in complement activation.- Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE.- DAF as a therapeutic target for steroid hormones: implications for host pathogen interactions.- Targeting gC1qR domains for therapy against infection and inflammation.- The Alternative C5a Receptor Function.- The effects of selective complement- and CD14-inhibition on the E. coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and tissue factor functional activity in human whole blood.- CR2-Mediated Targeting of Complement Inhibitors: Bench-to-Bedside Using a Novel Strategy for Site-Specific Complement Modulation.- Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anti-complement strategies.- Defective Complement Action and Control Defines Disease Pathology for Retinal and Renal Disorders and Provides a Basis for new Therapeutic Approaches.- C3 Glomerulonephritis/CFHR5 Nephropathy is an endemic disease in Cyprus: Clinical and molecular findings in 21 families.- Complement-targeted therapeutics in periodontitis.- Complement system activation in cardiac and skeletal muscle pathology: Friend or foe?.- Innate immunity as orchestrator of bone marrow homing for hematopoietic stem/progenitor cells.- Complement-mediated microvascular injury leads to chronic rejection.- Targeting complement at the time of transplantation.- Evaluation of the blood compatibility of materials, cells and tissues: Basic concepts, test models and practical guidelines.- Highly Multiplexed Proteomic Platform for Biomarker Discovery, Diagnostics and Therapeutics.- Complement in Action: A Review of Patent Trends From 1976 through 2011.

Bibliographic information

  • Book Title Complement Therapeutics
  • Editors John D. Lambris
    V. Michael Holers
    Daniel Ricklin
  • Series Title Advances in Experimental Medicine and Biology
  • Series Abbreviated Title Advs Exp. Medicine, Biology
  • DOI
  • Copyright Information Springer Science+Business Media New York 2013
  • Publisher Name Springer, New York, NY
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-1-4614-4117-5
  • Softcover ISBN 978-1-4899-7823-3
  • eBook ISBN 978-1-4614-4118-2
  • Series ISSN 0065-2598
  • Series E-ISSN 2214-8019
  • Edition Number 1
  • Number of Pages VIII, 320
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Immunology
    Infectious Diseases
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals